Herthena-Breast04三期临床试验已正式启动,该试验旨在评估帕妥珠单抗德鲁替康在转移性激素受体阳性、Her2阴性乳腺癌患者中的疗效,这些患者此前均已接受过内分泌治疗。
Herthena-Breast04三期临床试验已正式启动,该试验旨在评估帕妥珠单抗德鲁替康在转移性激素受体阳性、Her2阴性乳腺癌患者中的疗效,这些患者此前均已接受过内分泌治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.